



We invite you to join us for  
**Beyond Glaucoma 2021:**

## Time for Glaucoma - Are We Seeing Clinical Practice Clearly?

**Friday 24th September 16:00 – 18:30 Belgian time**

OR\*

**Saturday 25th September 10:00 – 12:30 Belgian time**

*\*you can choose your preferred day, the program is identical for both days*

**REGISTER HERE**

**Registration deadline: 16 September**

We look forward to bringing the eye care community together for a memorable and meaningful virtual event with live and on-demand engaging content

### ► Meet the experts:



Ingeborg Stalmans  
Belgium



Jonathan Crowston  
Singapore



David Crabb  
UK



Anthony Khawaja  
UK



Francisco Goñi  
Spain



Herbert Reitsamer  
Austria



Marta Pazos  
Spain



Antonio Fea  
Italy



Ike Ahmed  
Canada



Paul Harasymowycz  
Canada



Nathan Kerr  
Australia



Yi Xing  
China

### ► Agenda

Friday 24/9	Saturday 25/9	Virtual platform to open for viewing resources and pre-recorded content one hour before live event	
16:00 – 16:07	10:00 – 10:07	Beyond 2021: Welcome and Introduction	Ingeborg Stalmans, MD (Belgium) – Chair Jonathan Crowston, MD (Singapore) – Chair
16:07 - 16:27 10 mins presentation / 10 mins Q&A	10:07 - 10:27 10 mins presentation / 10 mins Q&A	<b>PLENARY: Current Challenges in Glaucoma</b>	<b>Jonathan Crowston, MD</b>
16:27 - 16:47 10 mins presentation / 10 mins Q&A	10:27 - 10:47 10 mins presentation / 10 mins Q&A	Living with Glaucoma: Visual disability and quality of life	<b>Prof David Crabb, Ph.D. Vision Science (UK)</b>
<b>2020 EGS Guidelines - The Impact on Medical and Surgical Management of Primary Open-Angle Glaucoma Part I - Medical Management &amp; SLT in Depth</b>		<b>Moderated by Jonathan Crowston, MD</b>	
16:47 – 16:58	10:47 - 10:58	A Closer Look: The latest EGS therapeutic algorithm	<b>Anthony Khawaja, MD (UK)</b>
16:58 – 17:06	10:58 – 11:06	A Closer Look: Are we achieving the most with medical treatment in early Glaucoma?	<b>Francisco Goñi, MD (Spain)</b>
17:06 - 17:17	11:06 - 11:17	Q&A session	<b>ALL</b>
17:17 - 17:25	11:17 - 11:25	<b>**Break**</b>	
<b>2020 EGS Guidelines - The Impact on Medical and Surgical Management of Primary Open-Angle Glaucoma Part II - Glaucoma Surgery in Depth</b>		<b>Moderated by Ingeborg Stalmans, MD &amp; Herbert Reitsamer, MD</b>	
17:25 - 17:33	11:25 - 11:33	The optimal union of the right patient at the right time	<b>Marta Pazos, MD (Spain)</b>
17:33 - 17:45	11:33 - 11:45	Pearls and pitfalls for an Ab Interno approach	<b>Antonio Fea, MD (Italy)</b>
17:45 - 18:00	11:45 - 12:00	Ten tips to optimise an Ab Interno approach	<b>Ike Ahmed, MD (Canada)</b>
18:00 – 18:25	12:00 – 12:25	Q&A session	<b>Moderated by Ingeborg Stalmans, MD &amp; Herbert Reitsamer, MD</b>
18:25 – 18:30	12:25 – 12:30	Conclusions	<b>Chairs</b>
<b>Extra sessions</b>			
18:45 – 19:00 15 mins Q&A	12:45 – 13:00 15 mins Q&A	XEN 45 in the Clinic – A Session of Case Studies	<b>Paul Harasymowycz, MD (Canada)</b>
<b>On-Demand Video</b>	Meet the researcher: 'Primary Needling of the Ab Interno Gelatin Microstent Reduces Postoperative Needling and Follow-up Requirements'		<b>Nathan Kerr, MD (Australia)</b>
<b>On-Demand Video</b>	What does the evidence say?: 'The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis'		<b>Yi Xing, MD (China)</b>

Adverse events should be reported to the local authorities and to Allergan:  
[safety.belgium@allergan.com](mailto:safety.belgium@allergan.com) / +32 479 42 32 97

This meeting is a promotional event organized and funded by Allergan, an AbbVie Company.  
 This meeting is based on UK product licenses, registration conditions and licences differ internationally, please refer to your country Directions For Use and [prescribing information](#).

XEN is a class III medical device CE 2797. Medical devices have associated risks, please refer to the contraindications, warnings and precautions sections in the [Directions For Use](#).

Privacy Policy  
 Your privacy is important to us. Allergan will treat personal information provided at registration for this meeting as confidential and will hold your personal information in compliance with the applicable data protection laws.

To view our Privacy Policy please go to <https://www.abbvie.com/privacy>  
 All faculty are paid consultants to Allergan, an AbbVie company.

These presentations are the property of the speaker and must not be recorded.  
 BE-NPR-2150020 – August 2021.

